RT Journal Article
SR Electronic
T1 Plasma biomarkers for diagnosis of Alzheimer’s disease and prediction of cognitive decline in individuals with mild cognitive impairment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.18.22272912
DO 10.1101/2022.04.18.22272912
A1 Pia Kivisäkk
A1 Thadryan Sweeney
A1 Becky C. Carlyle
A1 Bianca A. Trombetta
A1 Kathryn LaCasse
A1 Leena El-Mufti
A1 Idil Tuncali
A1 Lori B. Chibnik
A1 Sudeshna Das
A1 Clemens R. Scherzer
A1 Keith A. Johnson
A1 Bradford C. Dickerson
A1 Teresa Gomez-Isla
A1 Deborah Blacker
A1 Derek H. Oakley
A1 Matthew P. Frosch
A1 Bradley T. Hyman
A1 Anahit Aghvanyan
A1 Pradeepthi Bathala
A1 Christopher Campbell
A1 George Sigal
A1 Martin Stengelin
A1 Steven E. Arnold
YR 2022
UL http://medrxiv.org/content/early/2022/04/19/2022.04.18.22272912.abstract
AB Background The last few years have seen major advances in blood biomarkers for Alzheimer’s Disease (AD) with the development of ultrasensitive immunoassays, promising to transform how we diagnose, prognose, and track progression of neurodegenerative dementias.Methods We evaluated a panel of four novel ultrasensitive electrochemiluminescence (ECL) immunoassays against presumed CNS derived proteins of interest in AD in plasma [phosphorylated-Tau181 (pTau181), total Tau (tTau), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP)]. 366 plasma samples from the Massachusetts Alzheimer’s Disease Research Center’s longitudinal cohort study were examined to differentiate definite AD, other neurodegenerative diseases (OND), and cognitively normal (CN) individuals. A subset of samples were selected to have longitudinal follow up to also determine the utility of this plasma biomarker panel in predicting 4-year risk for cognitive decline in individuals with different levels of cognitive impairment.Results pTau181, tTau and GFAP were higher in AD compared to CN and OND, while NfL was elevated in AD and further increased in OND. pTau181 performed the best (AD vs CN: AUC=0.88, 2-fold increase; AD vs OND: AUC=0.78, 1.5-fold increase) but tTau also showed excellent discrimination (AD vs CN: AUC=0.79, 1.5-fold increase; AD vs OND: AUC=0.72, 1.3-fold increase). Participants with MCI who progressed to AD dementia had higher baseline plasma concentrations of pTau181, NfL, and GFAP compared to non-progressors with the best discrimination for pTau181 (AUC=0.82, 1.7-fold increase) and GFAP (AUC=0.81, 1.6-fold increase).Conclusions These new ultrasensitive ECL plasma assays for pTau181, tTau, NfL, and GFAP detect CNS disease with high specificity and accuracy. Moreover, the absolute baseline plasma levels of pTau and GFAP reflect clinical disease aggressiveness over the next 4 years, providing diagnostic and prognostic information that may have utility in both clinical and clinical trial populations.Classification of Evidence This study provides Class II evidence that plasma levels of pTau181, tTau, NfL, and GFAP are associated with AD and that pTau181 and GFAP are associated with progression from MCI to AD dementia.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: The submitted work was supported by NIA, NIAID, NIH, NIH Division of AIDS, NIMH, NINDS, the Harvard NeuroDiscovery Center, and the Michael J Fox Foundation. PK, CC, GS, MS, and SEA are named as co-inventors on a US patent application related to neurological biomarker assays that is jointly held by Massachusetts General Hospital and Meso Scale Diagnostics. KAJ has served as paid consultant for Bayer, GE Healthcare, Janssen Alzheimer's Immunotherapy, Siemens Medical Solutions, Genzyme, Novartis, Biogen, Roche, ISIS Pharma, AZTherapy, GEHC, Lundberg, and Abbvie. He is a site coinvestigator for Eli Lilly/Avid, Pfizer, Janssen Immunotherapy, and Navidea. He has spoken at symposia sponsored by Janssen Alzheimer's Immunotherapy, and Pfizer. BCD has received consulting fees from Acadia, Alector, Arkuda, Biogen, Denali, Eisai, Lilly, Merck, Novartis, Takeda, and Wave Lifesciences, royalties from Cambridge University Press, Elsevier, and Oxford University Press, and research grant support from NIH, Alzheimer's Association, and the Alzheimer's Drug Discovery Foundation. He has been advising for Merck, Wave LifeSciences, Arkuda, Axovant, and Alector. TGI has received funding from NIH, MassCATS, and Cure Alzhimer's Fund, and served on the Eli Lilly DSMB. DB has received funding from NIA, NINDS, and NIMH, has obtained compensation for serving on the Editorial Board of Belvoir Communications; and is on the Advisory Board of the National Cell Repository for Alzheimer's Disease and the Risk Evaluation Education for Dementia (AGREED) study. BTH has received funding from NIH, has served on an Advisory Board for Biogen, and he and/or his family has stock options in Novartis and Dewpoint. AA, PB, CC, GS, and MS are paid employees of Meso Scale Diagnostics, LLC. SEA has received honoraria and/or travel expenses for lectures from Abbvie, Biogen, and Eisai, and has served on scientific advisory boards of Corte, has received consulting fees from Abbvie, Boyle Shaughnessy Law, Cognito Therapeutics, Eisai, EIP Pharma, M3 Biotech, Orthogonal Neuroscience, and Risen Pharmaceutical Technology Co, Ltd, and has received research grant support from NIH, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Challenger Foundation, John Sperling Foundation, Abbvie, Amylyx, Athira Pharma, Chromadex, EIP Pharma, Janssen Pharmaceuticals, Novartis, SEER Biosciences, and vTv Therapeutics, and has served on an MSDB and/or Advisory Board for Allyx Therapeutics, Bob's Last Marathon, Cassava, Cortexyme, Sage Therapeutics, and vTv Therapeutics. TS, BCC, BAT, KL, LE, IT, LBC, SD, CRS, DHO, and MPF report no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis study was supported by NIA grant P30AG062421 (MADRC-LC study and biomarker core); NIH grant RF1AG059856 (Arnold lab); the Harvard NeuroDiscovery Center, with additional contributions from the Michael J Fox Foundation, NINDS grants U01NS082157 and U01NS100603, and the MADRC NIA grant P50AG005134 (Harvard Biomarkers Study); and by NIAID, NIA, and NIMH, Division of AIDS, of the NIH under award number U24AI118663 (Meso Scale Diagnostics). A. Aghvanyan, P. Bathala, C. Campbell, G. Sigal, and M. Stengelin are paid employees of Meso Scale Diagnostics, LLC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Mass General Brigham gave ethical approval for this work (2006P002104).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data not published within this article will be made available by reasonable request from any qualified investigator.